Alma Aurora Ramírez Hernández

Dr. Alma Aurora Ramírez Hernández


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2024 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
Juan Manuel Velázquez-EnríquezJuan Manuel Velázquez-Enríquez
Juan Manuel Velázquez-Enríquez
JSJovito Santos
Jovito Santos
AHAlma Aurora Ramírez Hernández
Alma Aurora Ramírez Hernández
EREdilburga Reyes-Jiménez
Edilburga Reyes-Jiménez
Laura Pérez-Campos MayoralLaura Pérez-Campos Mayoral
Laura Pérez-Campos Mayoral
RBRafael Baltiérrez-Hoyos
Rafael Baltiérrez-Hoyos

30 June 2026 in Biology
Verified
Journal Article
Open access
PDF file
RBRafael Baltiérrez-Hoyos
Rafael Baltiérrez-Hoyos
Juan Manuel Velázquez-EnríquezJuan Manuel Velázquez-Enríquez
Juan Manuel Velázquez-Enríquez
JSJovito Santos
Jovito Santos
DGDulce Natividad Jiménez Gómez
Dulce Natividad Jiménez Gómez
AHAlma Aurora Ramírez Hernández
Alma Aurora Ramírez Hernández
Verónica Rocío Vásquez-GarzónVerónica Rocío Vásquez-Garzón
Verónica Rocío Vásquez-Garzón
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease characterized by high mortality and marked clinical heterogeneity. A defining yet insufficiently understood feature of IPF is its frequent coexistence with pulmonary and extrapulmonary comorbidities. However, the molecular basis that underlies this multisystem involvement remains unclear. We applied an integrative systems-level framework that combines lung-derived transcriptomic datasets with curated disease–gene associations across major IPF-associated comorbidities. Network organization and functional stratification analyses were used to characterize shared and disease-specific molecular modules, and independent transcriptomic datasets were analyzed to evaluate the consistency of these patterns. These analyses revealed structured molecular convergence between IPF and its comorbidities organized into two interacting biological programs: a lung-enriched fibrotic–mechanical program and a systemically distributed neuroimmune–metabolic program. These programs are interconnected through a shared regulatory interface that includes IL6, AKT1, TGFB1 and STAT3. This organization was consistently observed across independent datasets. IPF emerges from the interaction between pulmonary and systemic regulatory programs rather than isolated lung-restricted mechanisms. This framework provides a basis for understanding disease heterogeneity and comorbidity burden, with potential implications for stratification and therapeutic targeting.